İsmail HASIRCI, Mine ADAŞ, Ahu KEMİK SARBAY, Özgür KEMİK, Sevim PURİSA, Sefa TÜZÜN, Ahmet Cumhur DÜLGER

Serum level of soluble vascular adhesion molecule 1 in patients with rectal cancer

Amaç: Vaskular adhezyon molekül-1 (VCAM-1), solid tümörlerin gelişimi ve/veya metastazında önemli rol oynar. Bu çalışma, rektal kanserde, serum soluble VCAM-1 düzeylerinin klinik önemini vurgulamaktadır ve onun lokal ekspressiyonun biologik önemini açıklamayı amaçlamaktadır. Metod: Rektal kanserli 90 hastanın ve 40 sağlıklı bireyin serum örnekleri, 84 hastanın da doku örnekleri toplandı. Serum ve kanser dokusunda serum VCAM-1 düzeyleri enzim bağlı immunosorbent ölçüm yöntemi ile ölçüldü. Bulgular: Soluble VCAM-1 düzeyleri, hasta grubunda kontrol grubundan anlamlı olarak yüksek bulundu. Artmış serum soluble VCAM-1 düzeyleri, klinikopatolojik parametreler ile ilişkilidir. Örneğin, tümör büyüklüğü, lenf nod metastaz varlığı, uzak metastaz ve zayıf prognoz gibi. Evre 2 ve evre 3 rektal kanserli hastalarda soluble VCAM-1 düzeyleri karşılaştırıldı. Ek olarak, soluble serum VCAM-1 düzeyleri ile kanser dokuları arasında korelasyon bulunamadı. Sonuç: Preoperatif soluble serum VCAM-1 düzeyleri hastalığın progressiyonunu yansıtmaktadır ve rektal kanser için sensitif bir biomarkırdı.

Rektum kanserli hastalarda serum VCAM-1 düzeyleri

Aim: Vascular adhesion molecule 1 (VCAM-1) plays an important role in solid tumor enlargement and/or metastases. This study evaluated the clinical significance of measuring serum levels of soluble VCAM-1 in rectal cancer and aimed to clarify the biologic significance of its local expression. Method: Serum was collected from 90 patients with rectal cancer and 40 healthy volunteers. Cancer tissue was collected from 84 patients. The level of soluble VCAM-1 in serum and cancer tissue was measured enzyme linked immunosorbent assay. Result: The mean soluble VCAM-1 level in patients was significantly higher than that in control subjects. Elevated serum soluble VCAM-1 was significantly associated with clinicopathologic paramaters such as tumor size, lymph node metastasis, distant metastasis, and poor prognosis. The prognosis for stage 2 patients positive for soluble VCAM-1 level was comparable to that for stage 3 patients. In addition, the serum level of soluble VCAM-1 level was not found correlation with the cancer tissue level. Conclusion: The preoperative level of soluble VCAM-1 level reflected disease progression and was a sensitive biomarker for rectal cancer.

PDF

___

1. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53.
2. Benson AB, Ajani JA, Catalano RB, et al. Recommended guide-lines for the treatment-induced diarrhea. J Clin Oncol 2004;22:2918-26.
3. Graziono F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026-38.
4. Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008;98: 143-7.
5. Font A, Abad A, Monzo M, et al. Prognostic value K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001;44:549-57.
6. Jernvall P, makine Mj, Karttunen TJ, Makela J, et al. Loss of heterozygosity at 18q21 is a indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J cancer 1999;79:903-8.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
8. Ivarsson ML, Bergstrom M, Eriksson E, Risberg B, et al. Tissue markers as predictors of postoperative adhesions. Br J Surg 1998;85:1549-54.
9. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracilbased chemotherapy. J Clin Oncol 2002; 20:1721-28.
10. Kim JG, Chae YS, Sohn KS, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62-6.
11. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6.
12. Karayiannakis AJ, Syrigos KN, Zhar A, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect f tumor surgery. Surgery 2007;131:548-55.
13. Kumar H, Heer K, Lee PW, et al. Preoperative serum Vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-85.
14. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005;104:2517-21.
15. Chin KF, Greenman J, Gardiner F, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-31.
16. Tamura M, Oda M, Tsunezuka Y, Matsumoto I, Kawakami K, Watanabe G. Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor. J Thorac Cardiovasc Surg 2004;128:517-22.
17. Higashiyama A, Watanabe H, Okumura K, Yagita H. Involvement of tumor necrosis factor alpha and very late activation antigen 4/vascular cell adhesion molecule 1 interaction in surgical-stress-enhanced experimental metastases. Cancer Immunol Immunother 1996;42:231-6.
18. Pigott R, Dillon LP, hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1, and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem BİOPHYS Commun 1992;187:584-9.